Medical vs Surgical Treatment in OSA Among Children
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Adeno-tonsillar hypertrophy causing OSA are treated surgically however, over the last years
it has been shown that montelukast or nasal steroidal spray can significantly improve
symptoms, adenoid size, and polysomnographic results in pediatric non-severe OSA, excluding
the need for surgery. A literature review from 2016 suggested that by using anti-leukotrienes
as anti-inflammatory appears to be beneficial in children with a non-severe OSA and can be
offered to parents as a treatment option before, or instead of surgery. In addition, nasal
steroidal spray may be considered useful in decreasing adenoid pad size and the severity of
symptoms related to adenoidal hypertrophy [9]. Despite emerging evidence that both
montelukast and nasal steroids are effective in the treatment of pediatric SDB, further
evidence is still required. . adeno-tonsillar hypertrophy causing OSA are treated surgically
however, over the last years it has been shown that montelukast or nasal steroidal spray can
significantly improve symptoms, adenoid size, and polysomnographic results in pediatric
non-severe OSA, excluding the need for surgery. A literature review from 2016 suggested that
by using anti-leukotrienes as anti-inflammatory appears to be beneficial in children with a
non-severe OSA and can be offered to parents as a treatment option before, or instead of
surgery. In addition, nasal steroidal spray may be considered useful in decreasing adenoid
pad size and the severity of symptoms related to adenoidal hypertrophy. Despite emerging
evidence that both montelukast and nasal steroids are effective in the treatment of pediatric
SDB, further evidence is still required.